Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

Frontiers in Oncology

Theresa Maatman¹  Nirav N. Shah²  Parameswaran Hari²  Bryon Johnson² 

[1] Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States;Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States;

关键词: CAR-T;    antigen escape;    B-cell NHL;    B-cell ALL;    immunotherapy;   

DOI  :  10.3389/fonc.2019.00146

来源: DOAJ

【 摘 要 】

Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen on B cells durable remissions have been achieved in patients with B cell non-Hodgkin lymphoma and acute lymphoblastic lymphoma. Despite impressive responses, multiple escape mechanisms to evade CAR-T cell therapy have been identified, among which the most common is loss of the target antigen. In this review we will highlight outcomes to date with CD19 CAR-T cell therapy, describe the current limitations of single targeted CAR-T therapies, review identified tumor escape mechanisms, and lastly discuss novel strategies to overcome resistance via multi-targeted CAR-T cells.

【 授权许可】

Unknown